LLY lilly.com: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Lilly - graphic logo of issuer LLY

Risks of raw material logistics disruptions and patent losses create external pressure, yet the EV/EBITDA multiple trend confirms the business resilience of Eli Lilly and Company (LLY), where the value of 29.86 expresses the metric level. A colossal influx of funds from bestsellers provides maximum demand inertia. Leadership in diabetes and obesity therapy forms a powerful defensive moat and guarantees a predictable free cash flow.

Lilly - LLY Enterprise Value to Operating Income Before Depreciation (period 11/23/2025 - 11/15/2026)

Eli Lilly - analytical breakdowns and key metrics (LLY)

- market price and analyst price targets:
Price Chart Lilly|LLY - Average Forecast Price
- company stock capitalization data:
Market Value Lilly|LLY - Total Company Value
- book value of equity indicators:
Book Value per Share Eli Lilly|LLY - Accounting Capitalization|Market Capitalization to Book Value Ratio lilly.com|LLY - Company Total Asset Base
- business debt structure and liquidity details:
Debt to Equity Eli Lilly and Company|LLY - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Lilly|LLY - Company Total Indebtedness|Debts to Book Capitalization Eli Lilly and Co.|LLY - Long-Term Debt|Company Short-Term Debt Eli Lilly|Quick Ratio lilly.com
- financial results and valuation multiples details:
LLY - Net Financial Result|Future Profit Eli Lilly and Company|LLY - Company Value to Net Income|Future Price to Earnings Eli Lilly|LLY - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Eli Lilly & Co.|LLY - Operating income before deduction of amortization|Earnings per share for the last twelve months Eli Lilly|LLY - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months lilly.com|LLY - Earnings per share growth in current year|Expected earnings per share growth for next year Eli Lilly and Company
- sales and revenue indicators:
LLY - Company Total Revenue|Company Future Sales Volume Eli Lilly and Company|LLY - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Eli Lilly
Basic company analysis:Lilly LLY
Original product of lilly.com

This indicator determines the total enterprise value, including debt, relative to its earnings before interest, taxes, depreciation, and amortization. By analyzing the EV/EBITDA multiple history of a business, an investor sees the real price of the asset, stripped of the influence of capital structure. A decrease in this ratio signals rising risks of undervaluation. For Eli Lilly and Company (LLY), stable demand for high-margin drugs guarantees a steady cash flow, minimizing the likelihood of a decline in this metric.

Competitor analysis

EV/EBITDA Multiple ABBV (AbbVie Inc.)|astrazeneca.com (AZN) - Company Value to EBITDA|NVS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MRK: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NVO: EV/EBITDA Multiple|AMGN (Amgen Corporation) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PFE (pfizer.com) - EV/EBITDA Multiple|sanofi.com (SNY) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BMS (BMY)|GlaxoSmithKline - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple TAK (Takeda Pharmaceutical Company)|TEVA: Enterprise Value to Operating Income Before Depreciation|Dr. Reddy's - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Viatris (VTRS)|Roivant Sciences (ROIV) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ZLAB (Zai Lab)|Enterprise Value to EBITDA Ratio BHC|Company Value to EBITDA Cosmos Health Inc COSM